Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum

Rhea-AI Summary

Longeveron (NASDAQ: LGVN) announced that its Chief Science Officer Dr. Joshua Hare and Chief Medical Officer Dr. Nataliya Agafonova will speak at the Global CardioVascular Clinical Trialists (CVCT) Forum in Washington, D.C., December 8-10, 2025.

The executives will join multiple panel discussions on cell therapy for heart failure, including delivery routes, cell types (mesenchymal stem cell therapy for dilated cardiomyopathy referencing POSEIDON and PATH AHEAD), and multi‑stakeholder debate on streamlining cell therapy innovation while maintaining evidence standards.

News Market Reaction – LGVN

-1.16%

1 alert

-1.16% News Effect

On the day this news was published, LGVN declined 1.16%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

CVCT Forum dates: December 8–10, 2025 Current price: $0.627 52-week range: $0.58–$2.24 +1 more

4 metrics

CVCT Forum dates December 8–10, 2025 Global CardioVascular Clinical Trialists Forum schedule

Current price $0.627 Pre-news trading level on 2025-12-03

52-week range $0.58–$2.24 52-week low and high before this announcement

Market cap $13,379,983 Equity value prior to the CVCT speaking news

Market Reality Check

Price: $0.5751 Vol: Volume 142,843 is 0.33x t...

low vol

$0.5751 Last Close

Volume Volume 142,843 is 0.33x the 20-day average 429,540, indicating muted trading interest before this update. low

Technical Shares at 0.627 are trading below the 200-day moving average of 1.16 and remain far under the 52-week high of 2.24.

Peers on Argus

LGVN was down 3.51% while peers were mixed: NBY rose 31.92%, whereas MTVA fell 9...

LGVN was down 3.51% while peers were mixed: NBY rose 31.92%, whereas MTVA fell 9.23%, SYBX fell 3.51%, and others saw smaller declines, pointing to stock-specific dynamics rather than a unified sector move.

Historical Context

5 past events · Latest: Dec 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 03	Conference speaking invite	Positive	-1.2%	Executives selected for multiple CVCT panels on cell therapy in heart failure.
Dec 02	Patent grant Canada	Positive	+2.2%	Canadian patent issued for laromestrocel in frailty and NIDCM through 2037.
Dec 01	Alzheimer’s biomarker data	Positive	-5.1%	Phase 2 CLEAR MIND MRI data showed reduced neuroinflammation vs placebo.
Nov 19	Alzheimer’s poster selection	Positive	-4.0%	Laromestrocel poster on neuroinflammation accepted for CTAD 2025 presentation.
Nov 12	U.S. patent grant	Positive	-1.3%	U.S. patent granted for treating aging-related frailty with inflammaging using MSCs.

Pattern Detected

Recent positive scientific and IP news has often coincided with flat-to-negative price reactions, with only one of the last five upbeat announcements seeing a positive 24-hour move.

Recent Company History

Over the last month, Longeveron has highlighted multiple advances around its mesenchymal stem cell programs. Patent grants in the U.S. and Canada extend protection for aging-related frailty and non-ischemic dilated cardiomyopathy through 2037–2038. Alzheimer’s data from the CLEAR MIND study were showcased at CTAD 2025, yet several such positive updates saw negative 24-hour reactions. Today’s CVCT speaking invitation continues this cadence of scientific visibility without immediate commercial inflection.

Market Pulse Summary

This announcement highlights added scientific visibility for Longeveron at the CVCT Forum, with seni...

Analysis

This announcement highlights added scientific visibility for Longeveron at the CVCT Forum, with senior leaders contributing to discussions on cell therapy delivery, cell selection, and heart failure strategy. It follows recent Alzheimer’s data and patent grants that expand protection into the late 2030s. Investors may watch how this visibility supports partnerships, clinical enrollment, and any follow-on updates to the company’s financial and regulatory disclosures.

Key Terms

cell therapy, mesenchymal stem cell therapy, dilated cardiomyopathy, intravenous

4 terms

cell therapy medical

"panel discussions on cell therapy for heart failure, including delivery routes, cell types"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

mesenchymal stem cell therapy medical

"Mesenchymal Stem Cell Therapy for Dilated Cardiomyopathy: Lessons from POSEIDON"

Mesenchymal stem cell therapy uses adult stem cells that can develop into bone, cartilage, fat or other tissue and are delivered to patients to help repair damage and reduce inflammation; clinicians harvest, expand or modify these cells before administration. Investors care because these therapies aim to create new treatment options across many diseases, representing large market potential but also high risk tied to clinical trial outcomes, regulatory approval, manufacturing challenges and safety—like backing a promising but unproven repair crew.

dilated cardiomyopathy medical

"Mesenchymal Stem Cell Therapy for Dilated Cardiomyopathy: Lessons from POSEIDON"

A condition in which the heart’s main pumping chamber becomes enlarged and weak, so it can’t pump blood as efficiently — think of a water pump with a stretched-out rubber bladder that loses pressure. It matters to investors because that weakness drives demand for medications, devices, hospital services and long-term care, influences clinical trial and regulatory activity, and can affect health-care costs, insurer liability and workforce productivity in related companies.

intravenous medical

"Intravenous Delivery of Cells/Cell Products: The Magic Bullet?"

Intravenous means delivering a drug, fluid or substance directly into a vein so it goes straight into the bloodstream. For investors, that matters because intravenous products often act faster, require different manufacturing, regulatory steps and healthcare settings (like hospitals or clinics), and can affect pricing, adoption and revenue profiles in ways that differ from pills or topical treatments — like turning a slow-release delivery into a direct tap to the system.

AI-generated analysis. Not financial advice.

MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, Dr. Joshua Hare, and Chief Medical Officer, Dr. Nataliya Agafonova, will speak on multiple panel discussions at the Global CardioVascular Clinical Trialists (CVCT) Forum taking place December 8-10, 2025 in Washington, D.C. The CVCT Forum seeks to promote rigorous evidence generation and accelerate the global impact of cardiovascular clinical trials.

Panel Discussions – December 8, 2025

Cell Therapy Heart Failure Trials – Cells Deliver and Disease Specific Strategies
Is Cell Delivery Route Important?
Intravenous Delivery of Cells/Cell Products: The Magic Bullet? Dr. Joshua Hare

What Type of Cells?
Mesenchymal Stem Cell Therapy for Dilated Cardiomyopathy: Lessons from POSEIDON and the PATH AHEAD – Dr. Joshua Hare

How to Streamline Cell Therapy Innovation, Not Compromising the Level of Evidence
The CVCT Multi-Stakeholder Think Tank Debate
Dr. Nataliya Agafonova, Panelist

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e9e96d9c-d6c3-4aec-ba85-36631b520211
https://www.globenewswire.com/NewsRoom/AttachmentNg/f106bde7-972a-4687-a91e-03e924f409fc

FAQ

When will Longeveron executives speak at the CVCT Forum (LGVN)?

Longeveron speakers will appear at the CVCT Forum in Washington, D.C., December 8-10, 2025.

Which Longeveron (LGVN) executives are presenting at the December 2025 CVCT Forum?

Dr. Joshua Hare (Chief Science Officer) and Dr. Nataliya Agafonova (Chief Medical Officer) are scheduled presenters.

What topics will Longeveron (LGVN) cover at the CVCT Forum panels on December 8, 2025?

Panels cover cell therapy heart failure trials, cell delivery routes, cell types (mesenchymal stem cell therapy), and innovation vs evidence standards.

Will Longeveron (LGVN) discuss results from POSEIDON and PATH AHEAD at the CVCT Forum?

Yes; Dr. Joshua Hare will discuss mesenchymal stem cell therapy for dilated cardiomyopathy with lessons from POSEIDON and PATH AHEAD.

How can investors learn more about Longeveron (LGVN) presentations at the CVCT Forum?

Investors can track the CVCT Forum agenda for session times and follow company updates for any public presentation materials.

Does Longeveron (LGVN) participation at CVCT Forum indicate new clinical data releases?

The announcement lists planned panel participation and topics but does not state any specific new clinical data releases or readouts.